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Abstract
Autoimmune diseases are characterized by recurrent attacks and remissions, but as a 
rule they progress and eventually cause a severe disability and death. The present chap-
ter contains general characteristics of autoimmune disease pathogenesis, ways to cause 
immune tolerance by hematopoietic cell transplantation (HCT), clinical aspects of the 
treatment for established autoimmune diseases with a special attention to multiple scle-
rosis (MS) and systemic sclerosis (SSc). A profound analysis of authors’ point of view and 
of the available literature has been performed. The promising results allows to consider 
HCT as a relevant treatment option for a certain autoimmune diseases.
Keywords: hematopoiesis, autoimmune diseases, immunomodulation, hematopoietic 
cells
1. Introduction
Autoimmune disorders are affecting from 5 to 10% of the population. Usually, they are char-
acterized by recurrent attacks and remissions, but as a rule they could develop with  fur-
ther progression and eventually development of a severe disability and death. The  usual 
treatment of the vast majority of autoimmune diseases is immunosuppression.  Newly pro-
posed pharmacological agents can cause pronounce effect for the disease  course and bring 
to a long-term remission. Evidences that certain autoimmune disorders can develop into a 
prolong treatment-free remission after hematopoietic cell transplantation (HCT) have been 
recently discussed in terms of human and animal models, including cases with accompanying 
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malignancies. The hypothesis that a strong immunosuppressive or myeloablative therapy can 
eliminate auto-reactive clones and cause a prolonged treatment-free remission is still open 
for analysis. It is still not clear whether myeloablative conditioning regimen with autologous 
HCT is more beneficial compared to a modern reduced intensity immune ablation with hema-
topoietic cell rescue. Other types of cell therapy are under intensive investigation at present 
too. Our present review will contain general characteristics of autoimmune disease pathogen-
esis, ways to cause immune tolerance (immunosuppression versus repertoire replacement), 
clinical aspects of HCT for established autoimmune diseases with a special attention to mul-
tiple sclerosis (MS) and systemic sclerosis (SSc), treatment regimens of autoimmune diseases 
and approaches for future therapies.
2. Back to immune tolerance: immunosuppression versus repertoire 
replacement and restoration of immune regulation
The treatment of autoimmune diseases, as pivotal goal, is to cause immune tolerance and 
therefore interrupt disease progression. The basic treatment of autoimmune disease is 
the immunosuppressive (and anti-inflammatory) therapy. In addition to different groups 
of cytotoxic immunosuppressive drugs, an increase in different types of monoclonal anti-
bodies is seen. All they are directed to damage the number or function of lymphocytes. 
Immunomodulatory approaches are also in the center of research evaluation and clinical 
trial, performed with some indications to show effectiveness of this concept. For example, 
intravenous IgG therapy has major effects on idiotypic network immune regulation and 
demonstrates clinical effectiveness in many autoimmune diseases.
Thus, due to decreasing lymphocyte infiltration, cytokine production and secondary inflam-
matory changes, a repair of misbalanced immune regulation and pathogenic and networked 
anti-idiotypic antibodies can lead to interruption of inflammatory attack, slowing disease 
progression, prolong life expectancy and improve the quality of life of patients with autoim-
mune diseases. However, most if not all patients should stay lifelong on their treatment, and 
ultimately in addition to the disease itself, an accumulation of side effects brings them to 
irreversible deterioration.
The first modern fashion hematopoietic cell transplantation (HCT) was performed in 1967 by 
Gatti et al. [1], but a few approaches for allogeneic transplantation before MHC/HLA discov-
ery were performed several years prior to them [2, 3]. If the aims of allogeneic HCT are the use 
of immune graft-versus-tumor effect or substitute the inborn or acquired error in hematopoi-
esis, the immunogenesis or metabolism will result accordingly. Autologous transplantations 
are performed with a goal to reach the highest tolerable level of cytotoxic antitumor effect 
saving hematopoietic system maximally intact and minimally impaired. The latter approach 
became standard of care for multiple myeloma and lymphomas, and in addition, it finds its 
place in some other malignancies (neuroblastoma, breast cancer, etc.).
Myeloablative conditioning with subsequent hematopoietic cells rescue (autologous trans-
plantation) can re-establish the life-saving three lineage hematopoiesis, usually fast enough; 
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the white blood cells, the platelets, and the red blood cell engraftment occur in most of the 
cases within 2–3 weeks, registered in the vast majority of patients.
But while innate immunity usually restores in a few weeks, it takes much more time for 
recovery of adaptive immune system. In fact, despite a huge number of publications, there 
is no complex understanding concerning recovery of immunity after transplantation. 
What we exactly know is that this process is not simultaneous and that some segments of 
immune system can stay compromised for years. Those researchers, interested in specific 
details, can consider several resent reviews, but still majority of data are quantitative and 
fragmental [4].
Data concerning immune reconstitution after allogeneic HCT are dominating in medical liter-
ature. At the same time, there are less but still numerous publications and reviews concerning 
immune recovery after high-dose chemotherapy with hematopoietic cells rescue autologous 
 transplantation. Again, there are many specific details that are reviewed elsewhere [5] but 
major conclusions could be briefly seen here.
Comparison of autologous and allogeneic HCT in terms of modification of immune system 
shows that auto-HCT, in general, causes less long and less deep disturbance of immune 
function. In case of allogeneic transplantation, the most important and significant factors 
are conditioning regimen (e.g., a myeloablative, MA or non-myeloablative stem cell trans-
plantation, and NST), the use of serotherapy (e.g., antithymocyte globulin, ATG: more often 
late infections, more serious prevention of infections is necessary, etc.), graft manipulation 
(e.g., T repleted, T depleted and if depleted, then which way), prophylaxis, and treatment of 
developed graft-versus-host disease (GvHD) and procedures associated with the intensity 
and duration of immunosuppression.
Most of the mentioned factors are not existing in case of autologous transplantation by def-
inition. Conditioning regimens in all standard cases of auto-HCT are myeloablative. They 
cause short-term deep aplasia and mucosa injury which eventually restore fast enough. More 
ancient phylogenetic defense mechanisms and cells, such as granulocytes, monocytes and NK 
cells, recover usually in 2–4 weeks. Lymphopenia normally stays longer and can be profound 
for a year after transplantation. But adaptive immune defense mechanisms does not expose 
to immunosuppressive medications, to circulating for several weeks antilymphocyte antibod-
ies, GvHD (so-called autologous GvHD is more rare and much less severe and dangerous 
than GvHD after allogeneic transplantation), T cell depletion with need to rebuild acceptable 
quantity and repertoire of all lymphocyte subsets (except rare cases of graft purging by posi-
tive CD34+ selection), etc.
We can mention in advance that many of the rules of autologous transplantation are infringed 
in case of transplantation for autoimmune diseases; this will be discussed in details further 
in the text.
When immune reconstitution is discussed, the main attention goes to protection from infec-
tions and, in case of malignant diseases, to “graft-versus-tumor” effect. These factors shall 
govern and prevail treatment (transplant)-related mortality (TRM), overall survival (OS), 
and disease-free survival (DFS). Along with all that, there is one more aspect of immune 
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 reconstitution and this is a reconstruction of self-tolerance [6]. In case of application of trans-
plantation to autoimmune diseases, it becomes critical.
3. Concept
It is well established that the existing standard immunosuppressive/immunomodulating and 
anti-inflammatory treatment, even if prolonged, can lead to a remission, but the patient can 
never stay out of his or her medicamentous treatment and therefore cannot be defined as 
“cured.” Moreover, lifelong therapy is clearly associated with side effects of prolonged use 
of immunosuppressors and/or anti-inflammatory drugs; a list of complication consists of a 
range of systems involvement, starting from gastrointestinal tract damage from nonsteroidal 
anti-inflammatory drugs and finishing with complex Cushing’s syndrome due to steroids. 
Altogether, these complications tend to  infections,  cardiovascular problems, depression and 
social deprivation, and finally to a seriously compromised quality of life of these patients.
On the basis of this knowledge, the concept of total eradication of immune system, includ-
ing auto-aggressive clones and auto-reactive immune memory with subsequent rebuilding of 
“normal” self-tolerant repertoire, looks extremely attractive. The concept of reconfiguration, 
“resetting” of immune system using HCT, has the aim “to cure,” meaning to keep patient 
without disease progression and without any chronic disease-modifying antirheumatic drugs 
(DMARDs).
4. Background
Indeed and logically, there is enough background information to presume that HCT can be 
effective in autoimmune diseases according to our understanding of pathogenesis [7, 8].
Firstly, in the animal studies, a bulk of the experimental data is provided by models of syn-
geneic transplantations for adjuvant arthritis or collagen-induced arthritis (AA or CIA), for 
rheumatoid arthritis (RA) and experimental allergic encephalomyelitis (EAE) for multiple 
sclerosis (MS) on laboratory rodents [9]. It was clearly shown that the transplantation pro-
tects the cited conditions from relapse [10–12]. Similar effect was shown in autoimmune dis-
eases with other target organs [13]. Re-induction with antigen after such transplantation did 
not provoke a relapse, and curative effect was shown in case of substitution of syngeneic 
transplantation with autologous one and with different conditioning regimens (some of them 
were shown as inadequate) [10, 14, 15]. This effect brought some investigators to the conclu-
sion that at least some animal autoimmune diseases were stem cell diseases [16–18]. This still 
questionable opinion is in line with a few anecdotal observations of passive transfer of auto-
immune diseases from the donor by allogeneic HCT; examples include insulin-dependent 
diabetes mellitus, former name for type 1 diabetes (T1D), mellitus and hypothyroidism [19], 
toxic diffuse goiter [20], myasthenia gravis [21], and multiple sclerosis [22, 23].
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Our opinion, based on multiple published evidences that underestimation of specific local 
factors is incorrect, can be discussed. For example, transplantation performed in late stage 
of EAE leads to inferior outcomes [24]. Moreover, by monitoring of tracking of transplanted 
green fluorescent protein-transduced cells, the endogenous origin of microglia in advanced 
disease was shown. Host macrophages/microglial cells demonstrated robust activation and 
their number was higher in the stage of disease progression [25]. The same demonstration 
of different local trigger mechanisms can be made for systemic sclerosis (SSc), inflammatory 
bowel disease (IBD), rheumatoid arthritis (RA), and other autoimmune diseases.
Secondly, before 1995, there were several cases or small series reports of coexistence of auto-
immune diseases with other malignant conditions, which were the primary indication for 
HCT. After transplantation, the autoimmune diseases developed stable long-term remis-
sion, improvement of their symptoms, or alternatively proposed cure procedure. These cases 
included improvement or complete remission of RA by HCT for gold-induced aplastic  anemia 
[26–28], full remission of psoriasis and ulcerative colitis [29], and resolution of autoimmune 
hepatitis after HCT for leukemia [30]. In addition, Nelson et al. [31] have reported 13 patients 
with either preexisting autoimmune diseases (11 patients), or diseases that are possibly auto-
immune in nature (two patients), who underwent allogeneic HCT for the treatment of another 
pathology. None of these patients was found to have the autoimmune disease recurrence after 
HCT. However, there are other reports for patients whose RA have progressed [32] or had 
only a short period of relief from joint pain [33] following HCT.
5. Progress in transplantation for autoimmune diseases
The first report of HCT for autoimmune disease treatment as a primary indication was 
published in 1996 [57]. In the late 1990s of 20th century, a Joint Committee of the European 
League Against Rheumatism (EULAR) and the European Group for Blood and Marrow 
Transplantation (EBMT), joined by several North American and Australian centers, referred 
to as the International Autoimmune Disease Stem Cell Project, initiated a phase I/II study to 
assess feasibility, mortality, and preliminary response for this treatment model, performed 
for isolated autoimmune disease [34–36].
For over 20 years of experience, a reasonably big pool of clinical data of over thousands 
patients has been accumulated; this issue will be discussed in detail in the second half of 
this chapter. From the initial case reports, via small series and bigger retrospective group 
analysis, the studies came to phase II/III clinical trials. The concept of transplantation in 
autoimmune diseases itself has undergone a significant transformation. It looks naïve now, 
in terms of earlier views, when seriously discussed questions of syngeneic transplantations 
(which is casuistic), allogeneic transplantation (at present considered as too dangerous pro-
cedure for autoimmune disease, as potentially having incapacitating consequences, like 
GvHD) or absolutely indicated autoimmune transplantations (considered like panacea), 
were discussed [37].
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5.1. So, what was changed?
Initially, and this is still the dominant dogma, that transplantation is considered exclusively 
as prolonged immune suppression with rebuilding de novo immunopoiesis and therefore 
a tolerance. But comprehension is coming that this is only one side of the immune “reset-
ting” and HCT is not a simple immunosuppression. Reinfusion of hematopoietic stem cells 
after severe immunoablative causes regeneration of a new naïve immune repertoire from the 
patient’s thymus [38]. Moreover, autologous HCT probably causes restoration of immune 
regulation and abnormal FoxP3 function of CD4+CD25+ (Treg) cells, as one of the main patho-
genic mechanism of many autoimmune diseases [24, 39].
Gradually but persistently, conditioning regimens tend to undergo certain changes. In the 
first report of EULAR/EBMT, Tyndall (1999) [36] listed four main conditioning regimens 
that were used: (i) BEAM polychemotherapy (BCNU, VP-16, Ara-C, and melphalan) ± anti-
thymocyte globulin (ATG), (ii) CyATG, consisted of 200 mg/kg of cyclophosphamide (Cy) ± 
ATG, sometimes substituted with monoclonal antibodies, usually Campath (alemtuzumab, 
antibody targeted CD52-expressing cells: lymphocytes, monocytes and dendritic cells), (iii) 
busulfan and cyclophosphamide (BuCy), and (iv) Cy and total body irradiation, usually 8 Gy 
(CyTBI) ± ATG. BEAM-ATG till nowadays keeps its role as a central conditioning protocol 
despite the fact that it causes high rate of side effects, including life-threatening ones [40]. 
Non-myeloablative protocols based on maximal dose of cyclophosphamide demonstrate 
probably similar effectiveness with impression of lower toxicity [41, 42]. Other procedures 
of different reduced toxicity of immunoablative but not always myeloablative conditioning 
were published as well: mini BEAM-like, BCNU/CCNU with intermediate dose of melphalan, 
±ATG or alemtuzumab, rituximab, or Cy ± thiotepa or fludarabine, etc. Some could lead to the 
possibility of performing this procedure in outpatient manner [43–45].
Accompanying additional therapy is also improving during the entire period of analysis.
In other words, all discussed progressively resulting models developed different philosophy 
of autologous transplantations for autoimmune diseases, compared to other types of auto-
transplants (possibility to use non-myeloablative but immunoablative regimens, wide use of 
antilymphocyte antibodies, potential for reduction of toxicity, etc.). The critical advance of 
this evolution brings to major reduction of TRM from 20 to 30% up to very close to 0%. This is 
especially important when referred to application of HCT with early stages of slow progres-
sive diseases with life expectancy of dozens of years.
6. Potential effectiveness of HCT for specific diseases
HCT was reportedly applied to 2–3 thousands patients worldwide, and since 2010, the yearly 
number of HCT procedures registered has increased by 30%, reflecting a change in practice [46]. 
Despite major basic similarities between different nosology entities, neither data reliability nor 
even experience with hematopoietic cells transplantation was considered uniform. Therefore, 
quite a few specific details should be overviewed to make picture certain. Some diseases are 
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prevalent while some are rare; some can be long time controlled with minimal and available 
measures while some characterized with fast progression of severe disability and dramati-
cally shortened life expectancy. Altogether, this heterogeneous group of conditions, affecting 
8–10% of the population [47], but at present only for several forms of HCT, can be considered 
as an optional or investigational treatment. Phase I/II studies and then randomized trials have 
been designed for SSc, MS, IBD, RA, and chronic inflammatory demyelinating polyneuro- 
pathy (CIDP).
6.1. HCT for systemic sclerosis
SSc is a relatively rare connective tissue disease (prevalence ranged from 7 to 489 cases per mil-
lion individuals [48]). It is characterized by early vasculopathy, autoantibody formation, low-
grade inflammation, enhanced collagen synthesis, and fibrosis in skin and internal organs. 
Autoimmunity is triggered by antigens and has some genetic background, associated with 
loci at HLA-DPB1 and HLA-DPB2 [49], and several polymorphisms of other genes involved 
in immune regulation, including BANK1, C8orf13-BLK, IL-23R, IRF5, STAT4, TBX21, and 
TNFSF4 [50]. Both T and B lymphocytes are involved in the immune process, and it is accom-
panied by profibrotic cytokine production, such as transforming growth factor β (TGF-β) and 
connective tissue growth factor (CTGF), as well as fibroblast activation. It is interesting that 
many of the polymorphisms associated with SSc are shared with systemic lupus erythema-
tosus (SLE) and other autoimmune diseases; they reflect on their pathophysiological impor-
tance, but not for SSc as a separate nosology. Polymorphisms that have failed to be confirmed 
in follow-up studies include TGF-β and CTGF [51]. In the Caucasian cohorts, the associations 
were significant for SSc patients with either antitopoisomerase-1 or anticentromere autoanti-
bodies [50].
SSc is clinically characterized by extensive involvement of skin and visceral organs. For skin 
assessment, the modified Rodnan’s skin score (mRSS) is used: a semi-quantitative skin thick-
ness evaluation in 17 different body areas. Upon the degree of skin involvement, extended 
and limited SSc are differentiated. The extensive skin damage, associated with a degree of 
visceral organs involvement and the presence of heart, lung or renal disease, can increase the 
5 year mortality rate up to 40–50% [52–56].
In terms of such serious prognosis, SSc was one of the first reported cases of autoimmune dis-
ease where HCT was applied [57]. Since then, most of numerous small case series and phase 
I/II studies and three randomized trials demonstrated encouraging data.
The two randomized studies are described in detail and discussed in the present study: 
ASSIST performed by USA Chicago group [58]: a phase II study, including 19 patients, aged 
younger than 60 years, with diffuse SSc, mRSS of 14 or more, and internal organ involve-
ment or restricted skin involvement (mRSS < 14), but coexistent pulmonary involvement. The 
patients were randomly allocated in two equal groups to receive HCT (n = 10) or to receive 
1 g/m2 intravenous cyclophosphamide once per month for a period of 6 months (n = 9). The 
conditioning was non-myeloablative of intermediate toxicity, and consisted of 200 mg/kg 
intravenous cyclophosphamide and 6.5 mg/kg rabbit ATG, CyATG protocol. All 10 patients, 
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who received HCT, had no disease progression, and all 10 improved at or before 12 month 
follow-up, compared with none of nine treated with monthly cyclophosphamide (odds 
ratio 110, 95% CI 14.04–∞; p = 0.00001); eight of these nine controls had disease progression 
(p = 0.0001 versus HCT group), and 7 patients switched to HCT.
ASTIS [42] is an EBMT/EULAR phase III, multicenter, randomized, open-label, and parallel-
group clinical trial, conducted at 29 centers of 10 European countries. It included 156 patients 
between 18 and 65 years of age with mRSS 15, with disease duration of 4 years and involve-
ment of heart, lungs, or kidneys. In addition, inclusion of patients was allowed with dis-
ease duration of 2 years or less, and no major organ dysfunction as defined above provided 
they had an mRSS of ≥20 and an erythrocyte sedimentation rate greater than 25 mm/h and/
or hemoglobin less than 11 g/DL, not explained by causes other than active scleroderma. 
Patients were randomly assigned to receive HCT (n = 79) or cyclophosphamide (n = 77). The 
CyATG conditioning regimen was very similar to Chicago study (total cyclophosphamide 
200 mg/kg and intravenous rabbit ATG (Genzyme) in a total dose of 7.5 mg/kg). The dose 
of  cyclophosphamide in the control group was 750 mg/m2, repeated in 12 monthly pulses. 
During the first year, there were more irreversible events with organ failure or death in the 
HCT group, 13 (16.5%) versus 8 (10.4%) in the cyclophosphamide group. However, during 
the second year, the cumulative events were similar in both groups: 14 (17.7%) versus 14 
(18.2%). And by the 4-th year, the cumulative events in HCT group 15 (19%) were less than 
cyclophosphamide group 20 (26%).
At present, one more phase III clinical trial scleroderma: cyclophosphamide or transplantation 
(SCOT) [59] is completed but the results are not published yet. The SCOT protocol employs a 
lymphoablative preparative regimen, including 800 cGy TBI, delivered in two 200 cGy frac-
tions twice a day before CD34+ selected autologous hematopoietic stem cell transplantation 
[60]. The late results will be especially important to evaluate appearance of secondary malig-
nancies in association with the radiotherapy.
Therefore, employment of HCT has resulted in rapid and sustained improvement of skin 
thickening and functional ability, stabilization of major organ function with some improve-
ment of vital capacity in pilot studies, registry analyses, and the phase II–III trials. Some 
patients have achieved complete remission (CR) including unexpected and dramatic clinical 
and biopsy regression of dermal fibrosis as well as normalization of the microvasculature [61].
Despite an early treatment-related mortality rate of around 6–10%, potential long-term com-
plications and an increase in serious adverse events, HCT conferred a long-term survival 
benefit.
6.2. HCT for multiple sclerosis
In MS, a chronic inflammation of the central nervous system (CNS) is caused by an autoim-
mune reactivity of T cells toward CNS myelin components and therefore has classical autoim-
mune nature [62].
Primary susceptibility to MS in the majority of various populations is associated with HLA-
DrB1*15 [63, 64]. Recent genome-wide association studies (GWAS) identified multiple loci 
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affecting the risk of developing disease. The reported screen implicates a majority of these 
genes as immune related and coding for cytokine pathway (CXCR5, IL2RA, IL7R, IL7, 
IL12RB1, IL22RA2, IL12A, IL12B, IRF8, TNFRSF1A, TNFRSF14, TNFSF14), co-stimulatory 
(CD37, CD40, CD58, CD80, CD86, CLECL1) and signal transduction (CBLB, GPR65, MALT1, 
RGS1, STAT3, TAGAP, TYK2) molecules. In addition, some other genes are related to previ-
ously reported environmental risk factors such as vitamin D—CYP27B1, CYP24A1 and thera-
pies for multiple sclerosis including natalizumab—VCAM1 and daclizumab—IL2RA [65].
At present, four different clinical patterns of MS are considered: clinically isolated syndromes 
(CIS; the first attack of a disease compatible with MS), relapsing-remitting MS (RRMS; clearly 
defined relapses without or with minimal residual deficit upon recovery), secondary progres-
sive MS (SPMS, as a result of conversion of RRMS with or without occasional relapses and 
with gradual worsening), and primary progressive MS (PPMS, accumulation of disability 
from the very beginning of the disease and worse prognosis compare to RRMS/SPMS). The 
term progressive-relapsing multiple sclerosis (PRMS) is now obsolete [66].
The most commonly used rating scale to grade neurological disability in patients with MS is 
the expanded disability status scale (EDSS) [67].
Magnetic resonance imaging (MRI) is sensitive to focal CNS lesions and has been included in 
the diagnostic workup of patients in whom MS is suspected. Conventional MRI measures of 
the disease burden are useful tool to monitor the disease course.
Over the years, therapeutic approaches to MS were aimed at suppressing the immune system, 
in order to control the inflammatory process which causes the demyelination and finally irre-
versible axonal damage [68, 69].
The long list of registered therapies for MS includes corticosteroids (used mainly in a high-
dose fore acute attack), immunosuppressive and immunomodulatory drugs (such as gile-
nya, teriflunomide, dimethyl fumarate, etc.), cytokines (interferons, IFN-alpha and IFN-beta), 
and strong immunosuppressive modalities (alemtuzumab, natalizumab, mitoxantrone, and 
cyclophosphamide). In many cases, registered disease-modifying treatments do not provide 
satisfactory control of MS due to their inability to eradicate the self-specific T-cell clones and 
compartmentized inflammation in situ, which is less affected by the conventional modalities 
and seems to be the reason for lack of efficacy of any of the registered treatment models in the 
progressive phase of MS. That is why the best available conventional therapy has only partial 
beneficial effects [64, 70, 71].
According to the recent published databases from Europe, North America, and South 
America, multiple sclerosis (followed by SSc) is constantly the most common indication for 
HCT [48, 72, 73].
The pioneer publication of Fassas et al. [74] described a phase I/II study, involving 15 patients 
with progressive median EDSS of 6 (5–7.5). The patients were treated with BEAM protocol 
followed by autologous HCT and antithymocyte globulin (ATG). Results were encouraging: 
short time (6–18 months) neurologic improvements have been detected using EDSS in 7 of 15 
patients, and what was more obvious, using Scripps Neurologic Rating Scale (SNRS), which 
is more sensitive but not based predominantly on walking ability. One patient worsened 
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after 3 months and two have relapsed. There were no toxic deaths and reasonable number of 
side effects, mainly due to ATG infusion and infections during neutropenia. Since that time, 
BEAM-ATG became a gold standard for future trials and in use until nowadays.
The BEAM-ATG demonstrates its effectiveness in several trials, including the most recent ones.
The autologous hematopoietic stem cell transplantation trial in MS (ASTIMS) is promoted by 
the EBMT multicenter, randomized trial. Initiated as phase III study, it was transformed to 
phase II with a primary laboratory endpoint [40]. The aim was to compare BEAM-ATG with 
mitoxantrone 20 mg monthly for 6 months. The including criteria were SPMS or RRMS, with 
an increase of the EDSS in the last year, despite conventional therapy, and the presence of 
one or more active gadolinium-enhancing areas on MRI. Twenty-one recruited patients were 
randomized in either HCT (n = 9) or mitoxantrone (n = 12) arm. All but two patients were 
followed up for 4 years. The relapse rate was reduced in patients treated with HCT, when 
compared with mitoxantrone. HCT significantly reduced by 79% of the number of new T2 
lesions compared to mitoxantrone (median number 2.5 versus 8). In the AHCT group, no new 
gadolinium-enhancing lesions appeared on brain MRI, while 56% of patients treated with 
mitoxantrone presented at least one active lesion. Despite the fact that there was no treat-
ment-related mortality, serious adverse events (SAEs) were seen only in HCT arm. They were 
defined as life threatening in 2 patients at least. There were no deaths or late SAE. Adverse 
events were resolved without sequelae.
Another significant report was published by Burt’s group [75] and it includes a single insti-
tution (Chicago, USA), experienced with treatment of 145 patients with RRMS (n = 123), or 
treated on a compassionate basis SPMS (n = 28), and with a median follow-up of 2 years. The 
main group consisted of patients aged 18–55 years, and their including criteria were RRMS. 
The therapy was unsuccessful with ≥1 conventional drug, EDSS from 2.0 to 6.0, and during 
the preceding year, the patients had either ≥2 relapses or 1 relapse treated with a corticoste-
roid and additional gadolinium-enhanced lesions on MRI scan at a separate time.
The conditioning regimen consisted of 200 mg/kg of cyclophosphamide divided into four 
single daily doses, plus either 20 mg of alemtuzumab given 2 days before stem cell infu-
sion (22 patients) or 6 mg/kg of ATG (thymoglobulin), divided into five daily doses (129 
patients).
Prior to each antithymocyte globulin infusion, additionally 1 g of methylprednisolone was 
infused.
There was a significant improvement in disability defined as decrease in EDSS score of ≥1.0, 
with proportion of patients 50% (95% CI, 39–61%) in 41 of 82 for improvement at 2 years and 
64% (95% CI, 46–79%) in 23 of 36 for improvement at 4 years. The authors found a signifi-
cant decrease of T2 lesion volume. Several other evaluated scores demonstrated pronounced 
and statistically significant improvement including notable advance in total quality of life 
scores. Treatment-related mortality was 0% and overall survival was 99.3%; the only death 
that occurred 30 months after transplantation was due to cardiovascular disease.
Hamerschlak et al. [76] performed a direct comparison of BEAM-ATG and CyATG regimens 
in a prospective multicentric Brazilian MS trial. The authors found that the rate of compli-
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cations during transplantation was higher in the BEAM-ATG group (71.4%), compared to 
the CyATG group (40%; p < 0.04). Three subjects (7.5%) died of cardiac toxicity, sepsis, and 
alveolar hemorrhage, all of them from the BEAM-ATG group. The important conclusion was 
that despite the lower toxicity of CyATG, this regimen seems to be associated with the same 
outcome, but with lower toxicity, compared to BEAM-ATG.
Summarizing the cited protocols, with domination of BEAM and Cy (200 mg/kg), both ±ATG/
alemtuzumab make an impression that in case of MS, lower intensity protocols demonstrate 
lower, up to 0%, mortality rate, while OS and progression-free survival are similar; in resent 
studies, they range from 65 to 100%, far better than the results of conventional MS therapies 
[77–81]. Our limited experience demonstrates 71% of progression-free survival after non-
myeloablative transplantations performed in Hadassah-HUJI Medical Center (14 patients, 
1998–2016, 12 after autologous and 2 after allogeneic transplantation; S. Savin, R. Or, M. 
Shapira and I. Resnick; unpublished data).
The risk of treatment-related mortality in HCT conventionally perceived to be unacceptably 
high. In a similar approach, the vein statistical analysis demonstrates a decrease in TRM to 
1.3%, according to an analysis of the EBMT registry [82], and 0% in the most recent published 
profound enough series. The major role resulting from the studies is the development and 
choosing of less toxic conditioning protocols and adequate patient selection.
It is clear that there is a need for a solid phase III trial of HCT, firstly, for aggressive forms of 
MS and effectiveness of save low toxicity immunoablative conditioning for less incapacitating 
patients. There are several ongoing trials. A prospective, randomized, controlled multicentre 
trial has been already outlined in a positioning article of Saccardi et al. [83].
6.3. HCT in rheumatoid arthritis and juvenile idiopathic arthritis
Rheumatoid arthritis (RA) is affecting approximately 1% of the population. It is characterized 
by autoantibody production with progressive joint destruction due to the formation of an 
inflammatory hypertrophied synovium, erosion of the synovial cartilage and the surround-
ing bone [84]. Break of tolerance causes accumulation of immune effector cells, including 
macrophages and osteoclasts, DCs, B and T cells, especially Th17 subsets. Reduced T-cell 
receptor (TCR) excision circles and shortened telomeres result in a contracted TCR repertoire 
in both naïve and memory cells [85, 86].
An adequate control and a possibility of remission are usually limited to early-stage disease.
Pilot studies of HCT in RA date back to middle 1990s of the 20th century. It was shown that 
sustained remission responses were shortly activated for up to 6–12 months, which was fol-
lowed by reintroduction of DMARDs/anti-TNF therapy. Following HCT, there was a some-
what better response to DMARDs supporting the immunomodulating effect of HCT. There 
has been variable success of HCT in RA, but the results have not been encouraging as com-
pared to diseases like SSc or MS [87–89].
Published data from the EBMT registry showed no transplant-related mortality of RA patients 
with OS 98%, while in JIA patients, TRM was detected in 7 of 65 patients [90].
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At present, HCT for RA or JRA, in general, cannot be recommended, and can be considered 
very seriously only in context of RA/JRA oriented well-established clinical trials.
6.4. HCT in systemic lupus erythematosus
SLE is a prototype autoimmune disease with prevalence of 20–150 cases per 100,000 pop-
ulations. It is characterized by wide abundance of self-reactive antibodies, including those 
against nuclear and cytoplasmic antigens, as well as autoimmune activity associated with 
complement activation [91]. A typical characteristic of SLE is an extremely variable clinical 
manifestation that can make the diagnosis difficult and late.
The plasma cells are key players in pathogenesis of SLE. The immunological hallmarks of the 
disease are short-lived (HLA-DRhigh) plasmablasts, which are easily detectable in the circula-
tion during active disease [92]; the upregulation of IFN-regulated gene transcripts, therefore 
IFN-α and its response proteins IP-10 and Siglec-1, are established markers for monitoring 
disease activity in SLE [93, 94]; finally, circulating Foxp3+ Tregs, especially Helios+ subpopu-
lation, are associated with disease activity [95].
Major visceral involvement and persistent disease activities are predictors of poor out-
come [96].
Treatment response varies in population subsets owing to the genetic composition and racial 
differences, as well as hormonal influences in both the adult and pediatric patients [97].
Immunosuppressive therapy is often protracted for adequate disease control and to minimize 
organ damage in patients with very high disease activity, but prolonged uses of corticoste-
roids and repeated courses of higher doses of immunosuppressant have resulted in unfavor-
able long-term disease-free outcomes or drug-free intervals [98].
Results of autologous HCT are less consistent. In an American trial by Burt et al. [99], reduced 
intensity HCT (Cy-ATG) in refractory SLE showed significant advantages of HCT in terms of 
progression-free survival and attenuation of nephritic symptoms in patients with SLE. The 
study (n = 50) showed promising results with respect to the Systemic Lupus Erythematosus 
Disease Activity Index (SLEDAI) score and such activity markers as ANA, anti-dsDNA and 
complement with increasing 5 year progression-free survival. There was either stabilization or 
reversal of organ dysfunction, including renal function. With a mean follow-up of 29 months, 
the 5 year probability of overall survival and disease-free survival (DFS) following HCT was 
84 and 50%. TRM was 2% (1/50).
In EBMT too, positive trends in progression-free and overall survival were noted but the 
numbers are less encouraging [44, 90, 100]. The last analysis of 28 patients, transplanted 
between 2001 and 2008 in eight centers of six countries, using a spectrum of conditioning 
protocols and with median follow-up of 38 months after transplantation, demonstrated that 
the 5 year overall survival was 81 ± 8%, disease-free survival was 29 ± 9%, and non-relapse 
mortality (NRM) was 15 ± 7%. OS tended to be lower when using intermediate as compared 
to low-intensity conditioning (p = 0.08). OS was not significantly associated with the presence 
of renal, neurologic or hematologic involvement or of SLEDAI >20 before ASCT, anti-dsDNA 
antibodies at mobilization or ex vivo graft manipulation.
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The 3 year NRM was 0% in the low-intensity conditioning versus 23 ± 10% in the interme-
diate-intensity conditioning (p = 0.13). It is interesting that DFS and relapse incidence were 
not associated with any immediate pretransplant variables, including the use of low versus 
intermediate conditioning regimens.
A follow-up study using third-generation “rituximab sandwich” conditioning regimen 
(CyATG + rituximab, a B cell targeted anti-CD20 monoclonal antibody) is ongoing [101].
6.5. HCT for Crohn’s disease
Crohn’s disease is a relapsing inflammatory disease, mainly affecting the gastrointestinal 
tract, and frequently is presented with abdominal pain, fever and clinical signs of bowel 
obstruction or diarrhoea with passage of blood or mucus, or both. It represents one of two 
major forms of IBD [102].
It is thought that the disease develops due to abnormal mucosal immune responses to the 
gut flora. GWAS identified >100 susceptibility loci to Crohn’s disease in Caucasians but their 
heritability is not fully explained [103, 104]. Recent studies revealed an altered local and cir-
culating T-cell phenotype, in particular involvement of Th17 cells and IL-21/IL-22-producing 
CD4+ T cells [105, 106].
Initially, it was a clear impression that HCT is an effective approach. After a few cases or small 
series reports [107–111], the important publication of Chicago group appeared in Blood, 2010 
[112] and demonstrated that in all 25 patients, who received CyATG with autologous stem 
cell, the risk to develop clinical remission with Crohn’s disease activity index (CDAI) < 150 
(inclusion criteria CDAI > 250) was open. Relapse-free survival was 91, 63, 57, 39 and 39% at 
1st, 2nd, 3rd, 4th and 5th year, respectively. Five years after transplantation, 70% of patients 
were in remission, 80% were steroid free and 60% medication free. There was no treatment-
related mortality. In line with other cell therapies, the non-myeloablative transplantation was 
considered as the best studied/investigated idea of Crohn’s disease treatment [102].
The EBMT paper came out in 2015 [113], presenting a parallel-group randomized clinical 
trial conducted in 11 European transplant units (Autologous Stem Cell Transplantation 
International Crohn Disease—ASTIC—trial); the medial follow-up was 1 year. Comparison 
of immunoablation, with use of the similar CyATG protocol and HCT (n = 23) and control 
treatment (n = 22), demonstrated no statistically significant in-between group differences in 
proportions of patients achieving sustained disease remission, with CDAI less than 150 in 
the last 3 months, or free of active disease. There was a statistically significant difference 
among patients able to discontinue active treatment in the last 3 months. There were 76 seri-
ous adverse events in patients undergoing HCT versus 38 in controls; 1 patient from HCT 
group died 20 days after the start of conditioning with postmortem evidence of sinusoidal 
obstructive syndrome (SOS). Whether the SOS, seen in the patient who died, may be an ago-
nal event in a septic patient with development of a fulminant liver failure, or it can be a result 
of endothelial injury induced by high dose cyclophosphamide, is still open for discussion.
Therefore, evaluation of presented experience of HCT for refractory Crohn’s disease is not 
straightforward; it makes further study highly necessary and strongly recommended.
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6.6. HCT in other autoimmune diseases
In accordance with the EBMT data for December 2016, from 2227 reported HCT for autoim-
mune diseases (exact numbers not yet published), the cumulative percent of afore-discussed 
five conditions (SSc, MS, SLE, RA with JIA, and Crohn’s disease) is 83% (data not yet pub-
lished). All cases of application of transplantation for other multiple autoimmune diseases are 
outnumbered. There are published reports giving some evidence that transplantation might 
be an effective treatment option in case of severe primary systemic vasculitis. For example, 
in 15 transplanted patients of different forms of vasculitis with an overall response rate of 
93% (46% complete), partial responses were observed [114]. HCT has been promoted in poly-
myositis/dermatomyositis, Sjogren’s syndrome, psoriatic arthritis and ankylosing arthritis, 
chronic inflammatory demyelinating polyneuropathy and autoimmune cytopenias, including 
hemolytic anemia, ITP, Evans syndrome and other rare combinations [115, 116]. Promising 
preliminary results were registered in small groups of patients with type 1 diabetes (T1D) 
from Brazil [117, 118], China [119, 120], and Poland [121]. Preliminary lessons from these 
small trials suggest that: (i) majority of patients can reach independence of exogenous insulin 
for a period of few months to years; (ii) according to our knowledge, there were no described 
transplant-related deaths; and (iii) diabetic ketoacidosis at onset, probably due to a severe 
depletion of islet cells, can be a poor predicting factor.
However, the experience with almost all autoimmune diseases, plus some others, recently 
included into clinical trials, is limited to allow any generally accepted conclusions.
7. Conclusion
HCT treatment has revolutionized the approach to autoimmune diseases treatment.
The results vary with different diseases, and there is certainly a special room for well designed 
clinical trials. Late results sometimes also provide surprises, tending to review the initial con-
cept. Does that mean that the existing data are not enough to make a decision-concerning 
transplantation, either a more positive one (for instance MS) or a more negative one (e.g., 
RA)? Specific issues vary significantly depending on the country’s social and economic cli-
mate, differences in medical system or medical insurance barriers, and legislation requiring 
third-party payers, and as a result, a large portion of patients cannot afford the best, or even 
equivalent “conventional” lifelong treatment. The majority of failures come in the form of 
TRM, as well as nonresponsiveness and high relapse rate [121]. The attempts to decrease the 
treatment toxicity, without sacrificing the efficiency, are directed to balancing the failure-to-
benefit ratio. Different conditioning protocols may be more appropriate at various stages of 
the disease, such as RRMS with EDSS <6 versus SPMS with EDSS > 6. However, the questions 
are still widely open for a profound discussion, because in many cases, the efficiency itself 
remains unclear (e.g., Crohn’s disease). Despite a sufficient number of open issues, the num-
ber of treated patients with very promising results, especially concerning SSc and MS pub-
lished in major publications in peer-reviewed prestige journals, already allow us to consider 
HCT, a relevant clinical option, for a successful treatment of certain autoimmune diseases.
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